14-73192712-G-C
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM1PM5PP2PP3_ModeratePP5_Very_Strong
The NM_000021.4(PSEN1):c.617G>C(p.Gly206Ala) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000173 in 1,614,032 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G206S) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000021.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 15 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PSEN1 | NM_000021.4 | c.617G>C | p.Gly206Ala | missense_variant | 7/12 | ENST00000324501.10 | NP_000012.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PSEN1 | ENST00000324501.10 | c.617G>C | p.Gly206Ala | missense_variant | 7/12 | 1 | NM_000021.4 | ENSP00000326366 | P4 |
Frequencies
GnomAD3 genomes AF: 0.000125 AC: 19AN: 152052Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000795 AC: 2AN: 251492Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135920
GnomAD4 exome AF: 0.00000616 AC: 9AN: 1461862Hom.: 0 Cov.: 31 AF XY: 0.00000275 AC XY: 2AN XY: 727234
GnomAD4 genome AF: 0.000125 AC: 19AN: 152170Hom.: 0 Cov.: 32 AF XY: 0.000148 AC XY: 11AN XY: 74384
ClinVar
Submissions by phenotype
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Mar 14, 2023 | This variant is statistically more frequent in individuals affected with Alzheimer disease (AD) than in the general population and/or healthy controls (Genome Aggregation Database (gnomAD), Cambridge, MA (URL: http://gnomad.broadinstitute.org)). This is considered a founder variant among individuals of Caribbean Hispanic ancestry (PMID: 11710891, 23114514, 25333068, 27073747). At least one other missense variant at this codon is considered to be pathogenic or likely pathogenic. This variant occurs as the most likely explanation for disease in a significant number of internal cases. Assessment of experimental evidence suggests this variant results in abnormal protein function. Studies show this variant results in increased amyloid-beta 42 peptide production (PMID: 11710891, 12119298, 27930341, 32032730). - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 31, 2022 | Published functional studies demonstrate a damaging effect resulting in an increase of the amyloid beta ratio (Pimenova et al., 2020); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 22312439, 11710891, 23383383, 22584618, 17522104, 23114514, 25333068, 11524469, 27312774, 27614114, 18797263, 26756738, 23885714, 22475797, 21952501, 20047059, 12119298, 30279455, 27073747, 27930341, 32032730) - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Apr 24, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Mar 06, 2023 | The PSEN1 c.617G>C; p.Gly206Ala variant (rs63750082) is reported in the literature in several individuals and families affected with early-onset Alzherimer's disease, and is a founder in the Carribean Hispanic population (Athan 2001, Arnold 2013, Lee 2014, Ravenscroft 2016, see link to Alzforum database). This variant is reported in ClinVar (Variation ID: 18143), and is only observed on three alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. The glycine at codon 206 is highly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Functional analyses of the variant protein show an impaired ability to properly cleave amyloid precursor protein, which can lead to increased amyloid plaque formation (Athan 2001, Sun 2017). Based on available information, this variant is considered to be pathogenic. References: Link to Alzforum database: https://www.alzforum.org/mutations/psen1-g206a Athan ES et al. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA. 2001 Nov 14;286(18):2257-63. Arnold SE et al. Frequency and clinicopathological characteristics of presenilin 1 Gly206Ala mutation in Puerto Rican Hispanics with dementia. J Alzheimers Dis. 2013;33(4):1089-95. Lee JH et al. Disease-related mutations among Caribbean Hispanics with familial dementia. Mol Genet Genomic Med. 2014 Sep;2(5):430-7. Ravenscroft TA et al. The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer's disease in Hispanics in Florida. Am J Neurodegener Dis. 2016 Mar 1;5(1):94-101. Sun L et al. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Abeta42 and Abeta40 peptides by gamma-secretase. Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E476-E485. - |
Alzheimer disease 3 Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 14, 2001 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 26, 2023 | Variant summary: PSEN1 c.617G>C (p.Gly206Ala) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 251492 control chromosomes. c.617G>C has been reported in the literature in multiple individuals of Caribbean ancestry affected with Alzheimer Disease, Type 3 (Example: Athan_2001). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function indicating an increase in amyloid-beta 42 peptide production (Athan_2001). Six submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. The following publication have been ascertained in the context of this evaluation (PMID: 11710891). All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pick disease;C0338451:Frontotemporal dementia;C1843013:Alzheimer disease 3;C3151038:Acne inversa, familial, 3 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 17, 2024 | This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 206 of the PSEN1 protein (p.Gly206Ala). This variant is present in population databases (rs63750082, gnomAD 0.003%). This missense change has been observed in individual(s) with early and late onset Alzheimer disease and Alzheimer disease (PMID: 11524469, 11710891, 18797263, 22312439, 23114514, 25333068, 27073747). It is commonly reported in individuals of Caribbean ancestry (PMID: 11524469, 11710891, 18797263, 22312439, 23114514, 25333068, 27073747). ClinVar contains an entry for this variant (Variation ID: 18143). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PSEN1 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects PSEN1 function (PMID: 11710891, 27930341). For these reasons, this variant has been classified as Pathogenic. - |
Pick disease;C0338451:Frontotemporal dementia;C1843013:Alzheimer disease 3;C3151038:Acne inversa, familial, 3;C3160720:Dilated cardiomyopathy 1U Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 04, 2022 | - - |
PSEN1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 13, 2024 | The PSEN1 c.617G>C variant is predicted to result in the amino acid substitution p.Gly206Ala. This variant has been previously documented to be causative for familial Alzheimer’s disease. It was reported to be a common cause of dementia in Hispanics in Puerto Rico and early-onset Alzheimer’s disease in Hispanics in Florida (Arnold et al. 2013. PubMed ID: 23114514; Ravenscroft et al. 2016. PubMed ID: 27073747). This variant is reported in 0.0056% of alleles in individuals of Latino descent in gnomAD. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at